Drugs

Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute

Photo of Robert Jotte from rockymountaincancercenters.com

Jul 1, 2024, 14:03

Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared on LinkedIn:

“Significant advancements in NSCLC treatment! SCRI’s Dr. Robert Jotte presents how Adagrasib shows improvement in PFS and ORR over Docetaxel in previously treated patients. Watch his detailed discussion on ecancer.”

Source: Sarah Cannon Research Institute/LinkedIn

Adagrasib ASCO24 cancer Cancer research clinical trials docetaxel ecancer immunotherapy NSCLC NSCLC treatment OncoDaily Oncology ORR PFS Robert Jotte Sarah Cannon Research Institute

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage